Progress in treatments for pediatric rheumatic diseases, collaborative clinical trials, and personalized therapeutic approaches highlight the past year in rheumatology
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis
Narcotic and non-narcotic pain regimens can be used
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
EULAR 2013: Drugs New and Old Could Treat Spondylarthropies
Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
Rheumatology Drug Research Should Focus on Particular Groups of Patients
An analysis of risks and benefits of drugs in specific types of patients will help rheumatologists provide better treatment
California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
A systemic lupus erythematosus (SLE) disease expert emphasizes benefits of hydroxychloroquine, burst of steroid treatments
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
- « Previous Page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- …
- 121
- Next Page »